EP0436526A1 - Anticorps contre l'angiogenine: agents immunotherapeutiques. - Google Patents

Anticorps contre l'angiogenine: agents immunotherapeutiques.

Info

Publication number
EP0436526A1
EP0436526A1 EP88907537A EP88907537A EP0436526A1 EP 0436526 A1 EP0436526 A1 EP 0436526A1 EP 88907537 A EP88907537 A EP 88907537A EP 88907537 A EP88907537 A EP 88907537A EP 0436526 A1 EP0436526 A1 EP 0436526A1
Authority
EP
European Patent Office
Prior art keywords
angiogenin
antibody
antibodies
antibody according
effective amount
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
EP88907537A
Other languages
German (de)
English (en)
Other versions
EP0436526A4 (fr
EP0436526B1 (fr
Inventor
James W Fett
Bert L Vallee
Edward M Alderman
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Harvard College
Original Assignee
Harvard College
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Harvard College filed Critical Harvard College
Publication of EP0436526A4 publication Critical patent/EP0436526A4/fr
Publication of EP0436526A1 publication Critical patent/EP0436526A1/fr
Application granted granted Critical
Publication of EP0436526B1 publication Critical patent/EP0436526B1/fr
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/808—Materials and products related to genetic engineering or hybrid or fused cell technology, e.g. hybridoma, monoclonal products
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/808—Materials and products related to genetic engineering or hybrid or fused cell technology, e.g. hybridoma, monoclonal products
    • Y10S530/809—Fused cells, e.g. hybridoma
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/827—Proteins from mammals or birds
    • Y10S530/828—Cancer
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/868—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof involving autoimmunity, allergy, immediate hypersensitivity, delayed hypersensitivity, immunosuppression, or immunotolerance

Definitions

  • Angiogenesis is the process of increased vascularization in response to an angiogenesis factor. It occurs as a result of the endothelial cells in the existing blood vessels being stimulated into mitosis, thereby producing a new capillary network which advances towards its stimulus.
  • Solid tumors in situ are supported by an extensive vascular network which supplies the tumor with nutrients and eliminates its waste.
  • This extensive vascular network is thought to develop from the host's normal and less extensive vascular network in response to the secretion of substances known as tumor angiogenesis factor.
  • Angiogenesis factors are not specific for tumors alone. Recently, an angiogenesis factor has been isolated from the joint fluid of patients suffering from the inflammatory disease, rheumatoid arthritis. This angiogenesis factor was isolated from the synovial fluid of the inflamed joint and was serologically identical with the tumor angiogenesis factor isolated from animals with experimental cancers. (Lancet 1, 682, Mar. 1980).
  • angiogenesis is associated with the pathological condition known as diabetic retinopathy and also with normal wound healing.
  • the present invention relates to antibodies specific for the human angiogenesis factor, angiogenin.
  • the antibodies of the present invention bind to the human angiogenin molecule inhibiting its activity, thereby inhibiting angiogenesis.
  • the antibodies of the present invention are useful agents for inhibiting angiogenesis in humans and other mammals such as in the treatment of tumors, diabetic retinopathy, inflammatory diseases, and disease states where angiogenesis is not desired.
  • Le.Veen U.S. Patent 4,529,590, describes a method for producing a bovine angiogenesis factor.
  • LeVeen's method consists of inducing a *prolonged inflammatory response in the cattle secondary to the injection of irritants into the body cavity of the animal.
  • the angiogenic material which LeVeen isolated from fluid at the site of irritation was only partially characterized; it tested positive for angiogenic activity on chick chorioallantoic membrane and was capable of evolving an immune response in animals but is distinguished from angiogenin by having an isoelectric point low enough to allow chromatography on an anion exchanger, such as DEAE cellulose.
  • angiogenin an angiogenic protein from human adenocarclnoma cell line HT-29.
  • Angiogenin was also described in Fett et al., Biochemistry, Vol. 24, pp. 5480-5486, (1985).
  • the present invention relates to antibodies specific to human angiogenin, and to therapeutic compositions containing them as well as their use in inhibiting angiogenesis in mammals.
  • This invention relates to the production of monoclonal and polyclonal antibodies (herein referred to as antibody) immunologically reactive with angiogenin, in particular, angiogenin having the amino acid sequence in Formula 1 below.
  • the antibodies can be raised by challenging mammals, e.g. mice or rabbits, either with angiogenin or with various fragments of angiogenin, prepared either by synthesis or by degradation of angiogenin itself.
  • the fragments of angiogenin used each contains one or more epitopes, functional subunits, or active sites.
  • Antibodies raised to such fragments may display less undesirable cross-reactivity with foreign proteins than do antibodies to whole angiogenin; • consequently, antibodies to fragments of angiogenin may produce fewer undesirable side effects when used therapeutically than do antibodies to whole angiogenin.
  • the antibodies raised to such fragments of angiogenin are immunologically reactive to whole angiogenin.
  • Rabbits are immunized in one of three ways. They are immunized by subcutaneous injections with a suspension comprising purified angiogenin conjugated to affinity gel beads which are emulsified in 1 ml of complete or incomplete Freund's adjuvant just prior to use. Alternatively, the 0 rabbits are injected subcutaneously with purified angiogenin and/or synthetic peptide derivatives, either conjugated to keyhole Limpet hemocyanin (KLH) or carrier-free, which is likewise emulsified in 1 ml of complete or Incomplete Freund's adjuvant immediately prior to injection.
  • KLH keyhole Limpet hemocyanin
  • mice are immunized " by injection with purified angiogenin or fragments thereof conjugated to affinity gel beads which are emulsified in complete Freund r s adjuvant just prior to injection.
  • affinity gel beads which are emulsified in complete Freund r s adjuvant just prior to injection.
  • the mice are preferably inj cted with the immunogen in the peritoneal cavity. Mice are also
  • angiogenin and/or synthetic peptide derivatives either conjugated to KLH or carrier- free, which Is emulsified in complete or incomplete Freund's adjuvant prior to injection.
  • the resultant purified antibody preparations contain . polyclonal antibodies raised to angiogenin or fragments thereof which are utilized in the therapeutic studies later described.
  • mice were immunized by subcutaneous or intraperitoneal injection of angiogenin or peptide derivatives of angiogenin in complete or incomplete Freund's adjuvant. Three days before the fusion, the mice were boosted with an intraperitoneal injection of angiogenin or peptide derivatives of angiogenin.
  • the monoclonal antibodies are partially purified from either hybridoma-conditioned media or ascites in a multistage process.
  • Hybridoma-conditioned media is clarified initially by filtration, preferably through glass fiber filters.
  • Ascites is produced in Charles River nu/nu outbred mice. The mice are primed with 1 ml of intraperitoneal injection of pristane followed 7 days later with an intraperitoneal injection of 1 x 10 hybridoma cells.
  • Ascites fluid is collected from the mice 1 to 2 weeks later, centrifuged to remove cells and frozen for subsequent purification.
  • Antibodies in the filtered hybridoma-conditioned media or ascites are precipitated by saturated ammonium sulfate, centrifuged to a pellet, decanted, resuspended in saturated ammonium sulfate, pelleted again, resuspended in normal saline (0.15 M NaCl, pH 7.4) and finally dialyzed against normal saline (0.15 M NaCl, pH 7.4).
  • the resulting solution is purified further by Protein A- Sepharose chromatography, dialyzed against normal saline, sterile filtered and stored in aliquots at -70°C.
  • Monoclonal antibodies were characterized by ELISA and radioimmunassay (RIA) for their ability to recognize other species of angiogenin such as bovine, porcine, and rabbit-derived angiogenin. In addition, mutants of angiogenin produced in our laboratory was used to characterize further the epitope binding of the monoclonal antibodies .
  • RIA radioimmunassay
  • mutants consisted of single amino acids substitutions: the lysine at residue 40 substituted with either glutomine (K40Q) or arginine (K40R.) , the arginine with residue 66 substituted with alanine (R66A) , tryptophan at residue 89 substituted with methionine (W89M) , and the aspartic acid at residue 116 substituted with histidine (D116H) or alanine (D116A) .
  • ARH angiogenin-bovine RNase A hybrids
  • the antibodies of this invention possess anti-tumor activity in mammals.
  • the antibodies of this invention prevented and inhibited tumor growth in mice as determined by immunoprophylactic and immunotherapeutic studies.
  • Fab and F(ab')2 fragments of antibodies to angiogenin should produce an analogous therapeutic effect since it is well known in the art that the Fab or F(ab')2 fragments of an antibody possess the antibody binding site and are capable of binding to the antigen as avidly as the intact antibody.
  • the immunotherapeutic agents of this invention are monoclonal and polyclonal antibodies, Fab and F(ab') fragments thereof, and mixtures thereof which are Immunologically reactive with angiogenin and/or with natural and/or synthetic peptide fragments of angiogenin.
  • These immunotherapeutic agents are useful medicaments in the treatment of pathological processes in mammals where angiogenesis Is an undesired manifestation of the process.
  • immunotherapeutic agents can inhibit angiogenesis, they are particularly useful In the treatment of tumors In mammals.
  • the immunotherapeutic agents of this invention can be administered in a wide variety of dosage forms, either alone or In combination with other pharmaceutically compatible medicaments, and in the form of pharmaceutical compositions suited for systemic or localized inj ection, time release implants and the like .
  • the immunotherapeutic agents of this invention are administered in the form of pharmaceutical compositions suited for injection consisting essentially of the free antibody and a pharmaceutical carrier.
  • the pharmaceutical carrier can either be a solid or semi-solid material, or a liquid in which the immunotherapeutic agent is dissolved, dispersed or suspended and which can optionally contain small amounts of pH buffering agents and/or preservatives.
  • Suitable buffering agents include for example sodium acetate and pharmaceutical phosphate salts and the like.
  • Pharmaceutically acceptable preservatives include for example benzyl alcohol and the like.
  • Representative of pharmaceutically effective dosage ranges are 6.6 ⁇ g to 66 ⁇ g of antibody/dose. However, therapeutically effective dosage ranges can be expected to vary based upon the avidity of the particular antibody selected, the size, age and weight of the patient being treated, and the like, and can readily be determined by simple experiment.
  • Example 1 Male NZW rabbits weighing 3-5 kg upon arrival were obtained from Mllbrook Farms, MA and maintained according to AAALAS guidelines.
  • Inbred Balb/c (Balb/CAnNCrlBR) mice used for immunization to provide spleen cells for hybridoma-producing fusions are purchased from Charles River Laboratories' VAF+ (virus antibody free) facilities.
  • Nude mice used for the tumor experiments as well as ascites production are also purchased from Charles River Laboratories. All mice are kept in autoclaved filter top cages in laminar flow, HEPA-filtered racks and are handled only by gloved and gowned personnel.
  • Example 2 Rabbit Polvclonal Antibody Preparations of angiogenin were conjugated to an affinity gel, Af IGel 10 (BioRad Laboratories, Burlingame, CA) , according to manufacturer's instructions, at concentrations of 5 ⁇ g (total protein)/ml settled beads. Unreacted sites on the beads were blocked using 1 M ethanolamine and the beads were then extensively washed with coupling buffer, then sterile distilled water. Fifty ⁇ l of 10% conjugated bead suspension was emulsified in 1 ml complete (or Incomplete) Freund's adjuvant immediately prior to injection.
  • Af IGel 10 BioRad Laboratories, Burlingame, CA
  • angiogenin and synthetic peptide derivatives were conjugated via glutaraldehyde to keyhold Limpet hemocyanln (KLH) at ratios of 50 ⁇ g/mg KLH.
  • KLH keyhold Limpet hemocyanln
  • the resulting solution was to 5 mg (total protein)/ml sterile distilled water.
  • Fifty ⁇ l (135 ⁇ g) KLH-conjugated angiogenin or peptide solution was emulsified in 1 ml complete (or incomplete) Freund's adjuvant Immediately prior to injection. All rabbits were injection subcutaneously at 10 day intervals dorsally, proceeding caudad. Adjuvant was alternated between complete and incomplete Freund's.
  • Sera was collected from rabbits by venipuncture of the marginal ear vein 5 days following each injection, and assayed for the presence of specific antibody by ELISA (enzyme linked immunosorbant assays) .
  • antibodies were also produced in rabbits by immunization with carrier-free angiogenin or synthetic peptide derivatives of angiogenin.
  • Rabbits were initially injected subcutaneously with angiogenin (50 ⁇ g) emulsified in complete Freund's adjuvant. Two subsequent injections were given at two week intervals of angiogenin (50 ⁇ g) in incomplete Freund's adjuvant. Sera was collected by venipuncture of the marginal ear vein 14 days after the third injection and tested for the presence of specific angiogenin-binding antibodies by ELISA (enzyme-linked immunosorbent assay). The rabbits continued to be injected once per month with 50 ⁇ g of angiogenin in incomplete Freund's adjuvant, with sera taken by venipuncture of the marginal ear vein 12 to 14 days after each injection.
  • Immunoglobulins were precipitated from sera by the dropwise addition of equal volumes of saturated ammonium sulfate. The resulting suspension was stirred for 1 hr. at room temperature, then centrifuged at 10,000 g. Pelleted material was washed with saturated ammonium sulfate, then resuspended in minimal volume of 0.15 M.NaCl, pH 7.4 (normal saline), loaded into 6000-8000 MW cutoff dialysis tubing, and dialyzed against normal saline. The dialyzed Ig fraction was then applied to a 5 ml bed of Protein A-Sepharose (Pharmacia Fine Chemicals, Piscataway, NJ) , and washed with normal saline.
  • Protein A-Sepharose Pharmacia Fine Chemicals, Piscataway, NJ
  • immunoglobulins were eluted from the column in 0.2 M glyclne-HCl,- pH 3.5. These fractions were neutralized by immediate collection into 0.1 volume of 1 M Tris-Cl, pH 8.0, pooled, and dialyzed as above. The dialyzed material was applied to a 20 ml bed of DEAE-cellulose and the leading fractions (unbound) were collected, pooled, dialyzed against distilled water, then lyophilized. ⁇ 0
  • mice were initially injected with 30 ⁇ g of angiogenin in complete Freund's adjuvant subcutaneously. Two more injections of 30 ⁇ g of angiogenin in incomplete Freund's adjuvant were given 10 days and 17 days after the initial injection. Three days before the fusion, mice were boosted with 30 ⁇ g of angiogenin in normal saline given as Intraperitoneal injection.
  • the mouse boosted with the angiogenin in saline was sacrificed and the spleen harvested.
  • a suspension of spleen cells was obtained by purging the spleen with serum-free medium using a 22 gauge needle.
  • the spleen cells were washed three times with 10 ml/wash of serum-free media.
  • the Sp2/0 or P3x63- Ag8.653 fusion partner myeloma cells to be used were also washed three times with serum-free medium.
  • the spleen cells were mixed with the myeloma cells at a 4:1 spleen to myeloma cell ratio.
  • the spleen- myeloma cell mixture was pelleted by centrifugation and placed in a water bath at 37°C.
  • One ml of filtered polyethylene glycol (PEG, 0.83 mg/ l in serum-free media) was added slowly over a 30 second interval.
  • PEG polyethylene glycol
  • 5 ml of serum- ree media was added over a 5 minute period followed by 14 ml of HAT media over a 1 minute period.
  • the cells were then centrifuged for 7 minutes and the supernatant discarded.
  • the cells were suspended In HAT media containing mouse peritoneal exudate cells (4 x 10 5 cells/plate) and plated into 96-well tissue culture plates at 200 ⁇ l per well.
  • HAT medium Seven days after the fusion the HAT medium was removed and replaced with HT medium. Wells were checked daily for colony growth. Supernatants from those wells exhibiting colony growth were assayed for angiogenin-binding antibodies by ELISA. Cells yielding supernatant containing angiogenin-binding antibodies were subcloned twice by limiting dilution.
  • Hybridoma-conditioned medium or ascites fluid was clarified by filtration through Whatman glass fiber filters. Equal volumes of saturated ammonium sulfate were added dropwise to the clarified hybridoma-conditioned medium and stirred for 1 hr. at room temperature. The mixture was centrifuged (10,000 g) for 10 minutes and the resulting pellet resuspended in saturated ammonium sulfate and washed by centrifugation. Pelleted material was resuspended in normal saline and dialyzed as above against normal saline.
  • Clarified hybridoma-conditioned medium or ascites fluid was dialyzed overnight at 4°C in 6000-8000 MW cutoff bags against 50 volumes 0.1 M sodium phosphate buffer, pH 8.0. This material was applied to a 5 ml bed of Protein A-Sepharose. Unbound material was washed from the column using 0.1 M sodium phosphate buffer, pH 8.0, and Ig enriched fraction eluted from the column in 0.1 M sodium citrate buffer, pH 3.5, and dialyzed against normal saline. The resultant fraction was highly purified, as evidenced by gel electrophoresis under reducing conditions which revealed as major bands only the light and heavy chains of immunoglobulins.
  • Example 4 Characterization of 26-2F monoclonal antibody The monoclonal antibody 26-2F (ATCC [American Type Culture Collection, 12301 Parklawn Drive, Rockville, Maryland, 20852] Deposit Number HB9766) was the result of the fusion of the spleen cells of an angiogenin-immunized Balb/c mouse with the P3x63-Ag8.653 myeloma line.
  • This monoclonal antibody is an IgGl/c. It binds strongly to angiogenin both in a solid phase ELISA and a soluble phase (RIA) . It does not bind to bovine, porcine, or rabbit angiogenin in a soluble phase inhibition assay for binding to iodinated angiogenin.
  • mutants react equally well with native human angiogenin: R66A, angiogenin clipped at positions 2 and 67, D116A, D116H, and ARH-1 which contains the fourth disulfide bridge of RNase A.
  • 51C9 reacts with peptides 36-46-BSA, 41-51-BSA, 81-91-BSA but not with 1-21-BSA. Additionally, the antibody does not recognize porcine or bovine angiogenin or RNase A and reacts poorly with rabbit angiogenin and mutants K40 , K40R, and W89M.
  • 51C9 recognizes an area on angiogenin spanning two discontinuous regions. Residue 89 is recognized since mutating this tryptophan to methionine reduces the affinity 30-fold. Residue 40 is also recognized since mutating this lysine to glutamine or arginine reduces the affinity 22-fold. Residue 37 is also a critical residue. When this residue is changed to arginine, as in the porcine and bovine angiogenin, 51C9 does not have much affinity. Since both porcine and bovine have Lys-40 and bovine angiogenin does not have Trp-89, the change of serine 37 to arginine might result in a 100- fold reduction in affinity.
  • residues 89, 37, and 40 reside in close proximity to each other.
  • residues 90, 38, 39 and 41 might make contact with 51C9.
  • the antibody binding pocket measures 34 x 12 x 7 angstroms or 7.9 x 2.8 x 1.6 amino acids. This more than accommodates these seven residues.
  • these two regions are predicted as strongly antigenic.
  • residues 89 and 38 are predicted to be the most accessible of all these residues.
  • 51C9 does not recognize a complex formed by angiogenin and placental ribonuclease inhibitor (PRI) . This implies that 51C9 and PRI ' recognize overlapping regions on the angiogenin molecule.
  • PRI placental ribonuclease inhibitor
  • mice Male nude mice (5-7 weeks old) were kept at 2-4 mice per cage. Experimental groups of 10 mice were randomized by cages prior to experimentation. In addition the order of injection of the control and experimental preparations was varied from each experiment and the person injecting the tumor cell preparation was not knowledgeable as to the nature of the material mixed with the cells.
  • mice were injected with 1 x 10 6 HT-29 cells mixed with the antibody to be tested in phosphate-buffered saline (PBS) on day zero. The cells were incubated with antibody and PBS for 5 minutes prior to 1.4
  • PBS phosphate-buffered saline
  • mice In the first two experiments, 88-06 and 88-07, two doses of the ammonium-sul ate-precipitated and protein A-Sepharose- chromatographed, ascites-derived 26-2F monoclonal antibody were given and compared with the PBS control. In the second set of experiments, 88-08 and 88-09, two sets of 10 mice each were given the lower dose of 26-2F and compared with the PBS control group as well as a set of mice given a subclass-matched nonspecific monoclonal, M0PC21 (Organon Teknika Corp., West Chester, PA).
  • Table 1 summarizes the results of the four experiments. Depicted are the percent of animals with tumors smaller than the smallest PBS (control) tumor as well as the percent of animals with no detectable tumor for days 7, 14, and 24. As compared with PBS and MOPC treatment, 26-2F administration decreases effectively tumor size in a high percentage of animals and protects completely against tumor development in several animals for at least one month after"the last"antibody Injection. In a test group of mice receiving polyclonal antibody, doses of antibody prepared against angiogenin-KLH (50 ⁇ g, 25 ⁇ g) were given two days prior to HT-29 cell administration (5x10 ⁇ cells) and on days 1, 4, 6, 8, 11 following tumor cell implantation.
  • angiogenin-KLH 50 ⁇ g, 25 ⁇ g
  • Example 8 Generation of Antibodies to Angiogenin Using Peptide Fragments
  • Synthetic polypeptides were prepared corresponding to the amino acid sequences of Formula I: 6-21, 108-121, and 15-26.
  • the polypeptide corresponding to the specified fragment of angiogenin was prepared by solid phase Merrifield synthesis on a polymer bead, then liberated with hydrofluoric acid and purified by high performance liquid chromatograph , procedures which are all well known. See Barany and Merrifield, Peptides, Vol. 2, Special Methods in Peptide Synthesis, Part A, p. 3, Ed. Gross and Meinhofer, Academic Press N.Y. (1980) and Merrifield, Adv. Enzymology, Vol. 33, 221-296 (1969).
  • Each such synthetic peptide fragment was coupled to KLH with glutaraldehyde by conventional procedures, and the products were dialyzed against physiological saline.
  • dialyzed products were used to immunize rabbits monthly subcutaneously with 100 mg peptide equivalents of the peptide/KLH mixtures employing, alternately, complete and incomplete Freund's adjuvant according to standard protocols. Blood samples were drawn monthly.
  • IgG was isolated from the immune serum by ammonium sulfate precipitation, Protein A-Sepharose chromatography, and DEAE ion-exchange chromatography to provide purified antibody. Immunoreactivity of each antibody toward the peptide fragment and toward native whole angiogenin was assessed by enzyme-linked immunosorbent assay (ELISA) . It was found that all three were immunoreactive to whole angiogenin. Other synthetic peptides have been prepared corresponding to fragments 30-41, 36-46, 48-61, and 108-123 of Formula I and are being used as immuno ens .
  • ELISA enzyme-linked immunosorbent assay

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La présente invention se rapporte à la production d'anticorps contre l'angiogénine ou contre des fragments d'angiogénie et à des procédés inhibant l'angiogénèse chez les mammifères, ces procédés consistant à administrer à des mammifères de tels anticorps ou des fragments Fab ou F(ab')2 de tels anticorps, afin d'inhiber l'activité angiogénique. La présente invention se rapporte en outre à des compositions pharmaceutiques comprenant des quantités d'anticorps thérapeutiquement efficaces, qui réagissent immunologiquement avec l'angiogénine et qui peuvent être administrés pour inhiber l'angiogénèse.
EP88907537A 1987-08-06 1988-08-05 Utilisation d'anticorps contre l'angiogenin: agents immunotherapeutiques Expired - Lifetime EP0436526B1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US83231 1987-08-06
US07/083,231 US4853219A (en) 1987-08-06 1987-08-06 Antibodies to angiogenin: immunotherapeutic agents
PCT/US1988/002590 WO1989000862A1 (fr) 1987-08-06 1988-08-05 Anticorps contre l'angiogenine: agents immunotherapeutiques

Publications (3)

Publication Number Publication Date
EP0436526A4 EP0436526A4 (fr) 1990-08-20
EP0436526A1 true EP0436526A1 (fr) 1991-07-17
EP0436526B1 EP0436526B1 (fr) 1996-01-17

Family

ID=22177021

Family Applications (1)

Application Number Title Priority Date Filing Date
EP88907537A Expired - Lifetime EP0436526B1 (fr) 1987-08-06 1988-08-05 Utilisation d'anticorps contre l'angiogenin: agents immunotherapeutiques

Country Status (13)

Country Link
US (1) US4853219A (fr)
EP (1) EP0436526B1 (fr)
JP (1) JPH02504512A (fr)
KR (1) KR920005691B1 (fr)
AT (1) ATE133075T1 (fr)
AU (1) AU618024B2 (fr)
CA (1) CA1341425C (fr)
DE (1) DE3854926T2 (fr)
DK (1) DK29490A (fr)
ES (1) ES2015349A6 (fr)
GR (1) GR1000430B (fr)
PT (1) PT88314A (fr)
WO (1) WO1989000862A1 (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5520914A (en) * 1987-08-06 1996-05-28 President And Fellows Of Harvard College Antibodies to angiogenin: immunotherapeutic agents
FR2623509B1 (fr) * 1987-11-19 1990-04-20 Centre Nat Rech Scient Proteine de 17 kd a action angiogenique, son procede d'isolement a partir de lait de mammiferes, compositions therapeutiques la contenant, procede de detection et/ou de dosage et reactifs immunologiques de detection et de dosage des angiogenines de mammiferes, de leurs homologues et de leurs fragments
US6929907B2 (en) * 1999-12-31 2005-08-16 North Carolina State University Methods and compositions for determining the purity of chemically synthesized nucleic acids
DK1399186T3 (da) 2001-06-13 2010-03-29 Armbruster Biotechnology Gmbh Lægemiddel til behandling af tumorer og disses metastaser under anvendelse af et bindemolekyle mod knogle-sialoprotein
EP2612870A1 (fr) * 2005-09-12 2013-07-10 The Regents of the University of Michigan Fusions de gène récurrentes dans le cancer de la prostate
JP5796267B2 (ja) * 2006-04-10 2015-10-21 フージョン アンティボディーズ リミテッド 治療法

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4229531A (en) * 1978-12-29 1980-10-21 Monsanto Company Production of tumor angiogenesis factor by cell culture
US4465669A (en) * 1981-03-18 1984-08-14 Max-Planck Gesellschaft Zur Forderung Der Wissenschaften E.V. Angiotropins of leukocytes and inflamed tissue, process for their biotechnical preparation, and pharmaceutical compositions thereof
US4503038A (en) * 1983-02-25 1985-03-05 The Regents Of The University Of California Extracellular nonmitogenic angiogenesis factor and method of isolation thereof from wound fluid

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4229532A (en) * 1978-12-29 1980-10-21 Monsanto Company Production of tumor angiogenesis factor by cell culture
US4273871A (en) * 1980-03-03 1981-06-16 Monsanto Company Production of angiogenic factor by cell culture
EP0110688B1 (fr) * 1982-11-30 1990-02-28 The Victoria University Of Manchester Production de facteurs angiogéniques
US4529590A (en) * 1982-12-27 1985-07-16 Leveen Robert F Production of angiogenetic factor
US4699788A (en) * 1984-08-20 1987-10-13 Trustees Of Boston University Angiogenic factor methods of extraction and method for producing angiogenesis
US4727137A (en) * 1985-04-17 1988-02-23 President And Fellows Of Harvard College Purified protein having angiogenic activity and methods of preparation
EP0234545A3 (fr) * 1986-02-24 1989-05-24 Clemens Prof. Dr. Sorg Facteur angiogénique humain purifié, procédé pour sa préparation et préparations pharmaceutiques

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4229531A (en) * 1978-12-29 1980-10-21 Monsanto Company Production of tumor angiogenesis factor by cell culture
US4465669A (en) * 1981-03-18 1984-08-14 Max-Planck Gesellschaft Zur Forderung Der Wissenschaften E.V. Angiotropins of leukocytes and inflamed tissue, process for their biotechnical preparation, and pharmaceutical compositions thereof
US4503038A (en) * 1983-02-25 1985-03-05 The Regents Of The University Of California Extracellular nonmitogenic angiogenesis factor and method of isolation thereof from wound fluid

Non-Patent Citations (11)

* Cited by examiner, † Cited by third party
Title
BIOCHEMISTRY, vol. 24, no. 20, 1985, pages 5486-5494, American Chemical Society; D.J. STRYDOM et al.: "Amino acid sequence of human tumor derived angiogenin" *
BIOLOGICAL ABSTRACTS, vol. 65, 15 May 1978, Biological Abstracts Inc., Philadelphia, PA (US); G.Y. SVET-MOLDAVSKII, no. 60257/ 74-76. 1977 *
BIOLOGICAL ABSTRACTS, vol. 65, 15th May 1978, abstract no. 60267, Biological Abstracts Inc., Philadelphia, PA, US; G.Y. SVET-MOLDAVSKII: "Tumor angiogenic factor and the possibilities of its application", & VOPR. ONKOL. (LENINGR) 23(8): 74-76. 1977 *
BIOLOGICAL ABSTRACTS, vol. 67, no. 11, 1979, abstract no. 67987, Biological Abstracts Inc., Philadelphia, PA, US; P. PHILLIPS et al.: "Tumour angiogenesis factor (TAF) and its neuralisation by a xenogeneic antiserum", & INT. J. CANCER 23(1): 82-88. 1979 *
BIOLOGICAL ABSTRACTS, vol. 67, no. 11, 1979, Biological Abstracts Inc., Philadelphia, PA (US); P. PHILLIPS et al., no. 67987/ 82-88. 1977 *
BIOLOGICAL ABSTRACTS, vol. 70, no. 11, 1980, abstract no. 72411, Biological Abstracts, Inc., Philadelphia, PA, US; A.M. SCHOR et al.: "Quantitation of extracts containing tumor angiogenesis factor by radioimmunometric assay and radioimmunoassay", & INT. J. CANCER 25(6): 773-780. 1980 *
BIOLOGICAL ABSTRACTS, vol. 70, no. 11, 1980, Biological Abstracts Inc., Philadelphia, PA (US); A.M. SCHOR et al., no. 72411/ 773-780. 1980 *
NATURE, vol. 256, 07 August 1975; G. KÖHLER et al., pp. 495-497/ *
NATURE, vol. 256, 7th August 1975, pages 495-497; G. KÖHLER et al.: "Continuous cultures of fused cells secreting antibody of predefined specificity" *
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE USA, vol. 84, April 1987, pages 2238-2241; R. SHAPIRO et al.: "Human placental ribonuclease inhibitor abolishes both angiogenic and ribonucleolytic activities of angiogenin" *
See also references of WO8900862A1 *

Also Published As

Publication number Publication date
PT88314A (pt) 1989-06-30
AU618024B2 (en) 1991-12-12
EP0436526A4 (fr) 1990-08-20
US4853219A (en) 1989-08-01
EP0436526B1 (fr) 1996-01-17
ATE133075T1 (de) 1996-02-15
KR890701130A (ko) 1989-12-19
AU2316688A (en) 1989-03-01
JPH02504512A (ja) 1990-12-20
WO1989000862A1 (fr) 1989-02-09
DK29490A (da) 1990-03-30
KR920005691B1 (ko) 1992-07-13
DE3854926T2 (de) 1996-05-30
ES2015349A6 (es) 1990-08-16
GR1000430B (el) 1992-07-30
DE3854926D1 (de) 1996-02-29
CA1341425C (fr) 2003-03-18
DK29490D0 (da) 1990-02-05

Similar Documents

Publication Publication Date Title
US6419928B1 (en) Monoclonal antibodies to transforming growth factor-beta and methods of use
US7227004B2 (en) Antibodies to vascular endothelial cell growth factor
Cerottini et al. The immunosuppressive effect of passively administered antibody IgG fragments
JP2544873B2 (ja) 液性アネルギ―を誘導するための組成物
DE69014137T2 (de) Immunogenische Zusammensetzungen gegen Gastrin-Peptide.
EP0157643A2 (fr) Anticorps à l'interleukine-2-humaine induite à l'aide de polypeptides synthetiques
JP2000152783A (ja) 免疫活性ペプチドおよび抗体ならびに抗アレルギ―処置におけるそれらの使用
JPH11510172A (ja) アレルギー性喘息の治療法
US4864019A (en) Antibodies to inhibin and conjugates produced therefrom
WO1996025175A1 (fr) Administration d'un anticorps monoclonal specifique a la cyclosporine, qui reagit de maniere croisee avec p24 gag de vih-1 pour traiter l'infection a vih
JPH05500600A (ja) スフィンゴ糖脂質に対する免疫応答を誘導する抗イディオタイプ抗体及びその使用
JPH02488A (ja) 抗ヒトｂｃｄｆモノクローナル抗体
US5520914A (en) Antibodies to angiogenin: immunotherapeutic agents
US5792744A (en) Proteins from mammalian liver
US5721211A (en) Compositions and methods for treating small cell and nonsmall cell lung cancers
EP0436526B1 (fr) Utilisation d'anticorps contre l'angiogenin: agents immunotherapeutiques
EP0525570A2 (fr) Anticorps anti-idiotypiques imitant le TNF
EP0972781A1 (fr) Polypeptides de la protéine S et leurs utilisations
EP0592600B1 (fr) Polypeptides de proteines s et leurs utilisations
Stevenson et al. Preparation and properties of FabIgG, a chimeric univalent antibody designed to attack tumour cells
JP4173557B2 (ja) ミエリン塩基性タンパク質のペプチドフラグメント類、それらの医薬組成物、及び多発性硬化症を治療するためへのそれらの使用
EP0471205A1 (fr) Anticorps monoclonaux liant à la protéine proto-oncogène TRK
CA2021739A1 (fr) Proteinesimmunostimulantes, anticorps polyclonaux et monoclonaux correspondants, hybridomes correspondants pouvant etre utilises a des fins de traitement et de diagnostic
JPH11310537A (ja) 温熱療法及び薬剤
JPH08113600A (ja) Ｍｒｐに対する抗体

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19900205

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE FR GB IT LI LU NL SE

17Q First examination report despatched

Effective date: 19930303

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AT BE CH DE FR GB IT LI LU NL SE

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: NL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 19960117

Ref country code: BE

Effective date: 19960117

Ref country code: AT

Effective date: 19960117

REF Corresponds to:

Ref document number: 133075

Country of ref document: AT

Date of ref document: 19960215

Kind code of ref document: T

REF Corresponds to:

Ref document number: 3854926

Country of ref document: DE

Date of ref document: 19960229

ITF It: translation for a ep patent filed
REG Reference to a national code

Ref country code: CH

Ref legal event code: NV

Representative=s name: E. BLUM & CO. PATENTANWAELTE

ET Fr: translation filed
PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SE

Effective date: 19960417

NLV1 Nl: lapsed or annulled due to failure to fulfill the requirements of art. 29p and 29m of the patents act
PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 19960831

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

26N No opposition filed
REG Reference to a national code

Ref country code: GB

Ref legal event code: IF02

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: GB

Payment date: 20030730

Year of fee payment: 16

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: FR

Payment date: 20030820

Year of fee payment: 16

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: CH

Payment date: 20030825

Year of fee payment: 16

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: DE

Payment date: 20030930

Year of fee payment: 16

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: GB

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20040805

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LI

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20040831

Ref country code: CH

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20040831

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: DE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20050301

GBPC Gb: european patent ceased through non-payment of renewal fee

Effective date: 20040805

REG Reference to a national code

Ref country code: CH

Ref legal event code: PL

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: FR

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20050429

REG Reference to a national code

Ref country code: FR

Ref legal event code: ST

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES;WARNING: LAPSES OF ITALIAN PATENTS WITH EFFECTIVE DATE BEFORE 2007 MAY HAVE OCCURRED AT ANY TIME BEFORE 2007. THE CORRECT EFFECTIVE DATE MAY BE DIFFERENT FROM THE ONE RECORDED.

Effective date: 20050805